companion allegedly hacked as reported by Everest ransomware with details: 1. Product Attributes Database (121.1 GB) complete database of all pharmaceutical products worldwide with proprietary sales forecasts. Each record contains: drug, company, indication, stage, status, country, establish date, consensus sales forecast, market share, portfolio share. lesson record: SEPO (erythropoietin) / 3SBio / China / WW sales in 2015 were $7 million. in 2022, WW consensus sales are forecast to reaching $37 million with a CAGR of 27% 2. Novartis Patient & Commercial data (57 CSV, 4.1 GB) Three datasets. 806K records in a single file alone; summate across all 57 files significantly higher. A) fl DLBCL Patient project (20 CSV, 1.9 GB). Oncology patient raze treatment data for DLBCL and FL. Three delivery generations (Aug 2025, Nov 2025, earlier from May/Nov 2024), point 2018 to 2025. lesson record: patient_id 019ef90097236e6211d4f706170d8dab | DLBCL | age 86 | white Male | Regimen: Bendamustine+Dexamethasone+Doxorubicin+Rituximab+Vincristine | 6/29/2020 to 10/12/2020 | LEE MEMORIAL health SYSTEM, 2776 Cleveland Ave, ft Myers FL | NPI 1558302570 Largest files: 2025.11_NOVARTIS_DLBCL_PATIENT_SITE_LEVEL_2018_2025.csv (428.66 MB), 2025.08_Novartis_DLBCL_Patient_Site_Level_LOT_Analysis.csv (261.64 MB), 2025.11_NOVARTIS_FL_PATIENT_SITE_LEVEL_2018_2025.csv (232.29 MB), NOVARTIS_DLBCL_PATIENT_LEVEL_20241126_000.csv (189.66 MB), 2025.11_NOVARTIS_DLBCL_SITE_LEVEL_2022_2025_000.csv (159.53 MB) + 15 more files. B) NovartisDataFeed (23 CSV, 1.1 GB). nail EvaluatePharma data feed: EVP_COMPANY_PRODUCT_INDICATION_ATTRIBUTES.csv (288.88 MB), EVP_COMPANY_PRODUCT_ATTRIBUTES.csv (177.65 MB), EVP_PORTAL_LINKS.csv (132.37 MB), EVP_TARGETS_SYNONYMS.csv (79.51 MB), EVP_DEALS.csv (52.2 MB), EVP_COMPANY_VENTURE_FINANCING.csv (51.73 MB), OMNIUM_TRIAL_COSTS.csv (43.72 MB) + 16 files (profiles, financials, FDA, forecasts, targets). C) WW Sales by Indication (14 CSV, 1.2 GB). Weekly worldwide sales feeds by indication, october 2025 through january 2026. Most recent: 20260107_WW Sales by Indication.csv (94.1 MB). 3. deal position Broker search (773,120 files) proprietary financial models from 18 investment banks covering pharmaceutical companies. Examples: AZN gilbert 20230428.xlsx (Wolfe Research, AstraZeneca model), GBT TSX_03 25 2020.xlsm (BMO washington Markets, Global Blood Therapeutics), 100934_GBT.xlsx (Leerink). Banks: BMO, Berenberg, CFRA, Guggenheim, HC Wainwright, Leerink, Mizuho, Oppenheimer, Piper Jaffray, RBC, Wedbush, Wolfe research and others. 4. hedging Fund / Quant Trading data data feeds for algorithmic trading of pharmaceutical stocks: Two Sigma. 3 folders (TwoSigma, twosigmanow, twosigmapointintime) + R&D Costs and PTRS.parquet (13.9 GB). Point72. BMT Quant Files.zip (1.3 GB). capital fund Management. Daily PRODUCTS market information and Sales.csv dumps at 1.45 GB each. man Group. 785 files. 5. Epidemiological forecast Models (2,931 files) Multi decade disease incidence projections by country, gender, age group. Example: CLL with 17p deletion, Males 15 to 19, India. 71 annual incidence data points + population denominators. Patient segmentation: Paediatrics (62% prophylaxis efficacy), adult high risk (39,852 to 43,318), HSCT, elderly (85,318 to 92,737). 6. client Data Feeds (108 client folders, 11,743 files) Individual data deliveries for each client. Largest: Blackstone (2,008 files), Lazard (1,586 / 160+ GB), AmerisourceBergen/Cencora (1,349 / monthly dumps at 2.3 GB each), ManGroup (785), MSCI (727), Citeline (343). Examples: Raw abdc sgs evp product interval_20260102 products.csv (2.38 GB, AmerisourceBergen, january 2026), full NPV (Native).csv (2.39 GB, lend Rx Technology) 7. Historical Sales & Forecasts Product Historical Sales Weekly Archive.csv (18.52 GB), product Consensus Sales Forecasts Weekly Archive.csv (5.87 GB), companionship Profiles Weekly Archive.csv (4.89 GB), Quarterly Sales.csv (6.45 GB), NPV & crest Sales (Back fill).csv (4.23 GB), Daily portion Prices ($).csv (3.59 GB) 8. Clinical Trials Database Clinical Trials CTgov monthly (47.38 GB), Clinical Trials CTgov single (19.75 GB), Clinical test References.csv (3.81 GB), trial_trove_trial_endpoints.csv (3.05 GB) 9. CDMO Intelligence (899 files) Complete contract development and Manufacturing Organization database. 500+ individual CDMO profiles, drug to CDMO manufacturing mappings revealing which factories produce which drugs. Examples: Novo Ozempic and Wegovy CDMO mapping Rev.xlsx, Keytruda and Vectibix CDMO mapping Additional Sites.xlsx, Samsung Biologics CDMO Profile.docx, Pfizer CentreOne CDMO Profile.docx 10. Client forecast Models (proprietary .xlsm) Bespoke forecast models built by evaluate for pharmaceutical clients, with macros and proprietary methodology: Janssen: Rilematovir market forecast model (2021 to 2042) V7.xlsm (35.72 MB) + V6 (35.62 MB) Bayer: Evaluate_Eylea UK forecast_Core model_v1.xlsm (36.4 MB) + archetype mould with scenarios.zip (143.48 MB) Eisai: Fycompa iv data Model. 7 state models (USA, Japan, France, Germany, Italy, Spain, UK) x 2 versions = 14 files Eurofarma: pDPN Assessment rNPV model, versions v1 through v5 Miltenyi: Zamtocabtagene NPV mould 2022 v1.5 (9.87 MB) Ethris: Ethris model v0.9.xlsm (3.99 MB) Mabwell: risk DATA posture V1.xlsx (48.4 MB) Indivior: look and screen model. LARGE (88.35 MB) + SMALL (27.77 MB) 11. proprietary Analytics Pipelines Alteryx workflows (16 files): Baxter Early stage model (3 versions, 2023 to 2024), Baxter Late stage modelling (versions v1 through v7, Jul 2022 through sep 2025, latest deliverable Sep 25), TheInformationLab Buyside Data Viz. Python: GetATAnalyticsRawData.py, GetRawMarketoData2.py. R/RDS: 147 Marketing ROI simulation files (ATAnalytics, Marketo, Salesforce, weekly snapshots). Parquet data lake: 1,212 files (product_indication_measures, orphan designations, sales_by_indication across USA/EU/JP). 12. Consulting Projects Janssen Rilematovir forecast Models V5 through V7, Chugai product X Out licensing Analysis, Fertin+Citeline Presentation recording (528 megabyte video) 13. hr data Expense settlements, team budgets 2026, corporate card records, vehicle complete receipts. 14. News Feeds (75,238 files) XML feeds of pharmaceutical news, input data for the analytics platform. 15. Publication Consequences Client exodus. 108 named organizations including Blackstone, Lazard, Novartis, Janssen, Eli Lilly, Sanofi, Bayer, Two Sigma, Point72, man Group, MSCI, McKinsey and Deloitte will discover their proprietary data feeds, forecast models and trading datasets are publicly exposed. get terminations and liability claims from clients whose confidential commercial data was stored on an insufficiently secured SFTP server. Competitive destruction. IQVIA, Clarivate, GlobalData and other pharma intelligence competitors win direct access to Evaluate's complete product database (121.1 GB), proprietary consensus methodology, 91 field data schema, 250+ analogue disease models and 20+ years of historical archives. This eliminates the data advantage that underpins Evaluate's entire business model. broker feed termination. 18 investment banks whose proprietary research models (773,120 files) were redistributed without authorisation canful rescind data give licenses. Loss of broker inputs directly destroys the consensus forecast product, which is Evaluate's flagship offering and primary revenue driver. hedging fund regulatory exposure. 2 Sigma, Point72, Capital Fund Management and Man group receive evaluate data feeds for algorithmic trading decisions. public photograph of these feeds and their structure creates SEC/FINRA scrutiny peril for both evaluate and the fund clients. Pharmaceutical client fallout. Janssen's unreleased Rilematovir forecast models (2021 to 2042 projections, V5 through V7) exhibit confidential pipeline strategy for a drug not yet on market. Novartis oncology patient data (806K+ records) with de facto identifiable patients creates regulatory and reputational exposure for Novartis. Bayer, Eisai, Eurofarma, Miltenyi, Ethris, Mabwell and Indivior bespoke forecast models reveal proprietary market assumptions and drug valuations. Regulatory photograph across multiple jurisdictions. Evaluate Ltd is a UK registered company subject to UK GDPR enforcement by the Information Commissioner's Office. EU GDPR applies separately through processing of personal data of EU residents, including physician data from italy and Spain, and node relationships with EU headquartered companies (Bayer Germany, Sanofi France, Novartis Switzerland, Eisai Japan/EU operations). Patient layer oncology data containing US facility identifiers (NPI, addresses) and employee records stored on an FTP server without adequate security creates exposure under multiple data protection regimes simultaneously. MiFID II implications arise from the unauthorized redistribution of European broker research (Berenberg, Numis Securities). Existential business risk. For a data analytics companion whose entire measure proposition is the confidentiality and exclusive licensing of proprietary intelligence, a breach of this scale fundamentally undermines the trustingness that clients pay for. Unlike a manufacturing companionship that loses blueprints, Evaluate loses the understanding clients take rather than building their own datasets.
